YES. The Hepatitis C Treatment Information Project just received an advance notification from BC’s Ministry of Health that the hepatitis C treatment Epclusa (generic name sofosbuvir / velpatasvir) will soon be considered for BC PharmaCare coverage.
Wednesday August 24, 2016 to MIDNIGHT ON Wednesday September 21, 2016 is tentatively when input will be sought.
Submitting Input to BC PharmaCare about Hepatitis C Treatments and Epclusa
The BC PharmaCare approval process seeks input from patients and caregivers or loved ones of those who have or have had hepatitis C. If you are a BC resident and answer YES to any of the following questions, you can complete a questionnaire and send BC PharmaCare your input into whether or not they should cover Epclusa:
- Do you have hep C?
- Are you a caregiver to someone who has hep C?
- Does your patient group represent patients who have hep C AND have you registered with PharmaCare to give input? (Learn more about registering your organization).
Please note that PharmaCare’s questionnaire for Epclusa input wont tentatively be available for another two weeks. The Hepatitis C Treatment Information Project will send the questionnaire’s link out when BC PharmaCare makes it available.
Epclusa is the first pan-genotypic hepatitis C treatment to be approved for use in Canada against all six hep C virus types. A pan-genotypic treatment is a treatment able to cure all six of the hep C virus types with high success rates against all six.
More Information about Epclusa
- Epclusa: An Information Sheet for an Approved Treatment
- Epclusa: Approved treatment for all hep C types
- Hepatitis C treatment Epclusa approved in Canada—key information by CATIE
- Gilead Canada‘s press release about receiving a Notice of Compliance (NOC) from Health Canada for Epclusa
- Epclusa’s Canadian product monograph by Gilead